News of Benito’s Hat growth investment makes the headlines in this morning’s publication of City AM! Read more via the link below. Benito's Hat eyes expansion after securing new funding https://t.co/v7h7swSNAg pic.twitter.com/mbLFrPs6Vo — City A.M. (@CityAM) August 6, 2018
Calculus Capital portfolio company Mologic announced today that they have commenced a clinical trial to evaluate the company’s urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis (CF) patients. The study aims to identify five urinary biomarkers associated with the onset of pulmonary exacerbation in adults with CF. It will also validate the use … Continued
London, 3 August 2018: Calculus Capital has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments. OBT has a strong pipeline of ‘immune-oncology’ (IO) therapies that are intended to provide more targeted, specialised treatment strategies for patients by recruiting the body’s immune system to recognise and attack cancer … Continued
Calculus Capital portfolio company Every1Mobile’s Head of Programme Design, Abi Gleek recently spoke at a DAI panel discussion on “Digital Health in International Development: Current Realities and Future Trends” in London. Abi shared insights from the U Afya programme in Nairobi, Kenya where Every1Mobile is working with mothers and mothers-to-be in informal settlements, to design a … Continued
CloudTrade’s technology – which has been patented in Europe, the US and Australia – enables companies to automatically process electronic documents such as invoices and sales orders received by email. The software extracts information from a human-readable, machine-generated document, such as a PDF, validates it and then converts it into a data file that is … Continued
The Enterprise Investment Scheme Association (EISA) has launched a new membership programme specifically aimed at Financial Planners and Regulated Advisers. And its FREE! Called the Financial Planning Programme, EISA aims to provide all individuals in the financial planning community with a forum for both representing your views and keeping you up to date with industry issues. … Continued
Calculus Capital portfolio company, Axol Bioscience Ltd., has launched their Human iPSC-derived Atrial Cardiomyocytes for the discovery and development of novel treatments and advancing our understanding of cardiovascular disease. As a human cell culture specialist they already provide custom services for disease modelling and drug discovery markets. Generated from the same donor as Axol’s highly validated … Continued
Scancell announced today that it has exercised its option to a worldwide commercial licence for the use of Ichor Medical Systems proprietary TriGrid® 2.0 electroporation delivery system with SCIB1, Scancell’s ImmunoBody® vaccine for the treatment of advanced melanoma. The new technology will be used in an upcoming cancer trial, specifically deployed in an upcoming phase … Continued
The Bioindustry Association held an informative webinar chaired by Calculus Capital Chief Executive John Glencross with panellists Michael Kipping- Innovation Lead at Innovate UK, Oliver Sexton- Investment Director at UK Innovation & Science Seed Fund and Kaivan Faria- Investment Analyst at Newable, on the topic ‘How to fund your biotech breakthrough.’ To listen to the webinar click here
Collagen Solutions PLC (LON:COS) CEO Jamal Rushdy and CFO Hilary Spence discuss with Proactive Investors the firm’s results for the year ended 31 March 2018. During the interview with Andrew Scott they discuss recent results, exciting projects and opportunities for the business. The company recently featured in a Calculus “Spotlight On” article containing further information about how the … Continued